Lit Matters #2: Does Point-of-Care Troponin Actually Save Time?

Point-of-care high-sensitivity troponin does not automatically shorten emergency department length of stay for suspected acute coronary syndrome. In a randomized ED trial, faster assay availability translated into only a 6-minute median LOS difference, with similar discharge timing and 30-day outcomes.

POC Troponin and ED Throughput

• Randomized trial signal: In 1,494 ED patients with possible ACS, point-of-care hs-troponin produced only a 6-minute median length-of-stay difference versus central lab testing, arguing against a meaningful throughput win.
• Disposition timing reality: Early discharge rates were essentially unchanged, with about 16% out by 3 hours and 38% by 6 hours in both groups, a useful reality check for crowded-department workflow claims.
• Safety outcome parity: Thirty-day death, myocardial infarction, readmission, and revascularization were similar between groups, suggesting point-of-care testing did not buy speed at the expense of short-term safety.
• Operational bottleneck lesson: An 8-minute assay does not solve a 3-hour ED visit when the limiting steps are clinician workflow, bed movement, and downstream processes. We get into those local bottlenecks in the episode.
• Implementation friction points: Point-of-care testing carries higher per-test cost, shifts work toward ED staff, and still had technical failures in 4.5% of randomized patients, all of which matter more than headline analyzer speed.
• Rule-out pathway context: Both arms used accelerated ACS pathways that paired hs-troponin with HEART score assessment, which likely narrowed any advantage from moving the assay closer to the bedside.